| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
This compound is a chemical reagent and does not have a specific biological target. Its role is in bioorthogonal chemistry. It is also an intermediate in the synthesis of the antiviral drug Valaciclovir (Valacyclovir), which targets viral DNA polymerases.
|
|---|---|
| ln Vitro |
This compound is not a drug; its activity is chemical. It possesses a reactive azide group that can participate in CuAAC click chemistry with alkynes under mild, biologically compatible conditions. This reaction is highly specific, fast, and generates stable 1,2,3-triazole linkages, making it a powerful tool for bioconjugation and chemical biology.
|
| ln Vivo |
Specific in vivo activity data for this azido-valine compound is not provided. As a synthetic intermediate or a chemical biology probe, it is generally incorporated into larger molecules (like peptides or polymers) or used to modify a drug. These resulting conjugates or final products may have in vivo activity, but the reagent itself is not administered as a therapeutic.
|
| Enzyme Assay |
An assay for this compound is not a biological receptor-binding assay but a chemical purity and reactivity test. High-Performance Liquid Chromatography (HPLC) is used to assess its purity (>98% typical). For functional testing, an analytical click chemistry reaction can be performed. The compound is reacted with a model alkyne (e.g., propargyl alcohol) in the presence of a copper (I) catalyst. The reaction progress is monitored by LC-MS to confirm the formation of the expected triazole product, verifying the integrity of the azide group.
|
| Cell Assay |
Cellular experiments would not be performed with this compound alone, as it has no biological activity. Instead, it could be used to modify a cell-permeable peptide. A typical protocol involves conjugating a peptide containing an alkyne to N3-L-Val-OH using CuAAC. The resulting peptide-triazole-valine conjugate is then purified and added to cells. The experiment would then assay for a biological effect related to the peptide (e.g., cellular uptake), confirming the utility of the conjugation method.
|
| Animal Protocol |
Information on specific in vivo animal experimental protocols for this compound is not applicable. A compound containing an azide for click chemistry would not be administered to an animal without first being conjugated to its target molecule. The in vivo study would be performed on the final conjugate, using animal models appropriate for the specific disease target (e.g., cancer).
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) data is not relevant for this reagent. If used as an intermediate in valacyclovir synthesis, the PK properties of the final drug are well-characterized, but they do not apply to the intermediate itself. The compound's chemical stability in various solvents is its primary property for research use.
|
| Toxicity/Toxicokinetics |
Toxicity data for this specific building block is not provided. Standard safety assessments would categorize it based on its functional groups; alkyl azides can be potentially explosive when concentrated, though small molecules are usually handled safely in solution. It is for research use only and not intended for human consumption.
|
| References |
[1]. Hassan M Faidallah, et al. Synthesis, antibacterial properties and 2D-QSAR studies of quinolone-triazole conjugates. Eur J Med Chem. 2018 Jan 1;143:1524-1534.
|
| Additional Infomation |
This compound is an azido-analog of the amino acid L-valine. The presence of the azide group makes it a key building block for bioorthogonal chemistry, allowing biomolecules to be labeled or modified without interfering with native biological processes. The cyclohexylamine (CHA) salt form improves its stability and handling as a solid.
|
| Molecular Formula |
C11H22N4O2
|
|---|---|
| Molecular Weight |
242.32
|
| Exact Mass |
242.174
|
| CAS # |
1217462-63-9
|
| PubChem CID |
66519949
|
| Appearance |
White to off-white solid powder
|
| LogP |
2.836
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
17
|
| Complexity |
218
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
C1CCC(CC1)N.CC(C)[C@@H](C(=O)O)N=[N+]=[N-]
|
| InChi Key |
YMXXCNHHCIMTCV-VWMHFEHESA-N
|
| InChi Code |
InChI=1S/C6H13N.C5H9N3O2/c7-6-4-2-1-3-5-6;1-3(2)4(5(9)10)7-8-6/h6H,1-5,7H2;3-4H,1-2H3,(H,9,10)/t;4-/m.0/s1
|
| Chemical Name |
(2S)-2-azido-3-methylbutanoic acid;cyclohexanamine
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : 125 mg/mL (515.85 mM）
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1268 mL | 20.6339 mL | 41.2677 mL | |
| 5 mM | 0.8254 mL | 4.1268 mL | 8.2535 mL | |
| 10 mM | 0.4127 mL | 2.0634 mL | 4.1268 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
